Key result
Higher baseline plasma adiponectin levels predicted a worse response to antidepressant monotherapy in 121 inpatients with major depressive disorder, independent of drug class and baseline severity.
Why the study?
Circulating adiponectin levels relate to antidepressant response, but its effect on response to antidepressants in a naturalistic setting required investigation.
Do baseline plasma levels of adiponectin predict the response to antidepressant monotherapy in patients with major depressive disorder?
Observational (n=121)
Do baseline plasma levels of adiponectin predict the response to antidepressant monotherapy in patients with major depressive disorder?
Higher baseline adiponectin levels predict a worse clinical response to antidepressant monotherapy in patients with major depressive disorder.
Answers are grounded in this paper and cite their sources.
Should not yet change practice for biomarker-guided antidepressant selection; leaves open whether baseline adipon.
OBJECTIVE: Produced by adipocytes, adiponectin crosses the blood-brain barrier to bind with specific receptors in the hypothalamus, brainstem, hippocampus, and cortex. In patients with major depressive disorder (MDD), circulating levels of adiponectin inversely related with antidepressant response to ketamine, and predicted a better response to multi-target drug combinations than to escitalopram. We investigated the effect of adiponectin on response to antidepressants in a naturalistic setting. METHODS: We assessed baseline plasma levels of adiponectin in 121 MDD inpatients, treated with antidepressant drug monotherapy based on clinical need (selective serotonin reuptake inhibitors, venlafaxine, duloxetine) in a specialized hospital setting. Severity of depression was weekly assessed with Hamilton scale ratings. RESULTS: Adiponectin plasma levels were higher in patients with MDD compared with healthy controls, and negatively influenced the pattern of antidepressant response (higher baseline levels, worse response) independent of the drug class and of the baseline severity of depression, and of age, sex, and body mass index. CONCLUSIONS: The identification of adiponectin as a predictor of antidepressant response to drugs of different mechanism of action, such as ketamine, SSRIs, and SNRIs, and both in experimental and in clinical settings, warrants interest for further study of its pathways to search for novel biomarkers and therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Benedetti et al. (2021) conducted an observational in Major depressive disorder (n=121). Baseline plasma adiponectin levels vs. Lower baseline levels was evaluated on Antidepressant response (assessed weekly with Hamilton scale ratings). Higher baseline plasma adiponectin levels predicted a worse response to antidepressant monotherapy in 121 inpatients with major depressive disorder, independent of drug class and baseline severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: